| Name | Title | Contact Details |
|---|
Enzyvant is also advancing the development of RVT-802, an investigational tissue-based biologic therapy for the potential treatment of primary immune deficiency associated with complete DiGeorge Syndrome. RVT-802 has been granted orphan drug designation, Breakthrough Therapy designation, Regenerative Medicine Advanced Therapy designation, and pediatric rare disease designation by the U.S. Food and Drug Administration. Enzyvant anticipates a potential BLA filing for RVT-802 in the first half of 2018. Enzyvant plans to develop treatments for additional rare diseases with high unmet need.
Institute for Clinical Evaluative Sciences is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Rodin Therapeutics is a Biotechnology company located in Cambridge, Massachusetts, United States.
Datavant connects healthcare data to eliminate the silos of healthcare information that hold back innovative medical research and improved patient care. We help data owners manage the privacy, security, compliance, and trust required to enable safe data sharing. Datavant`s vision is backed by Roivant Sciences, Softbank, and Founders Fund, and combines technical leadership and healthcare expertise. Datavant is located in the heart of San Francisco`s Financial District.
EMD Chemicals Inc. is a Gibbstown, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.